CMS proposed two mandatory Medicare demonstration programs intended to tie Medicare drug prices to international benchmarks, a policy derived from the administration’s most-favored-nation (MFN) pricing push. The agency outlined models that would apply to Part B and Part D purchases, aiming to lower federal spending and beneficiary out‑of‑pocket costs by aligning U.S. prices with peer countries. The proposals come alongside a series of voluntary pricing deals announced by the White House that target Medicaid and cash prices; stakeholders say the demonstrations would produce more measurable savings if implemented. The plans face legal and industry pushback and will require rulemaking and stakeholder engagement before launch. Observers note the demos could reshape negotiating leverage for manufacturers and affect launch strategies for new therapies. Readers should watch comment periods and potential legal challenges; implementation details (drug selection, reference baskets, and transition protections) will determine commercial and clinical impacts.